0.3567  -0.014 (-3.65%)		06-12 16:00
Open: 0.3633 High: 0.3821 Volume: 212,163		Pre. Close: 0.3702 Low: 0.3506 Market Cap: 4(M)

Short term
Mid term
Targets	6-month :	0.53	1-year :	0.64
Resists	First :	0.45	Second :	0.55
Pivot price	0.4
Supports	First :	0.3	Second :	0.24
MAs	MA(5) :	0.35	MA(20) :	0.41
	MA(100) :	0.4	MA(250) :	1.16
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	10.3	D(3) :	8
RSI	RSI(14): 44.5
52-week	High :	2.75	Low :	0.16

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ MGRX ] has closed above bottom band by 28.4%. Bollinger Bands are 9.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.38 - 0.38	0.38 - 0.39
Low:	0.35 - 0.35	0.35 - 0.35
Close:	0.35 - 0.36	0.36 - 0.36

Mangoceuticals, Inc. dedicates its operations to the creation, promotion, and distribution of a variety of health and wellness products and services specifically designed for men. These offerings are primarily delivered through a telemedicine platform. The company's product line includes treatments for erectile dysfunction, marketed under the 'Mango' brand. Consumers can purchase these items directly from its official online portal, mangorx.com. Established in 2021, Mangoceuticals, Inc. is headquartered in Dallas, Texas, and operates as an affiliate of Cohen Enterprises, Inc.

Mon, 01 Jun 2026
MGRX Technical Analysis & Stock Price Forecast - Intellectia AI

Sat, 30 May 2026
Number of shareholders of Mangoceuticals, Inc. – NASDAQ:MGRX - TradingView

Tue, 17 Mar 2026
Mangoceuticals files $73 million lawsuit against tech vendor - Investing.com

Fri, 06 Mar 2026
Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds - GlobeNewswire

Mon, 23 Feb 2026
Mangoceuticals’ Patented MGX-0024 Achieves Zero - GlobeNewswire

Fri, 20 Feb 2026
Mangoceuticals stock surges on TRT program growth - Investing.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Healthcare Information Services
Shares Out	0 (M)
Shares Float	17 (M)
Held by Insiders	1.343e+007 (%)
Held by Institutions	10 (%)
Shares Short	451 (K)
Shares Short P.Month	0 (K)

EPS	-1.595e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-4 %
Return on Assets (ttm)	588.4 %
Return on Equity (ttm)	-60.6 %
Qtrly Rev. Growth	414580 %
Gross Profit (p.s.)	-16.7
Sales Per Share	-50.18
EBITDA (p.s.)	95735.7
Qtrly Earnings Growth	-1.3 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-5 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.01
Price to Cash Flow	1.02

Dividend	0
Forward Dividend	231100
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.